title: Efficacy and safety of the H1N1 monovalent vaccine in renal-transplant recipients and dialysis patients.
abstract: BACKGROUND
  The (H1N)1v influenza virus infection emerged in 2009 as a serious disease in targeted populations. Herein, we report on the tolerability and efficacy of (anti-H1N1)v vaccination in dialysis and transplant patients.
  
  
  METHODS
  18 renal-transplant recipients (RTR) and 19 dialysis patients (DP) [12 patients treated with peritoneal dialysis (PDP), 7 patients treated with haemodialysis (HDP)] were enrolled. DPs received one monovalent H1N1 adjuvanted-vaccine injection, and RTRs received two unadjuvanted vaccine injections within a 21-day period. Serologic response was defined as a haemagglutination inhibition titre of > 40 (seroprotection) and/or at least a four-fold increase in antibody titre from baseline (seroconversion).
  
  
  RESULTS
  Seroprotection rate after vaccination was greater in DPs than RTRs (p = 0.007), as was seroconversion (p = 0.001). Serologic response was similar in PDPs and HDPs.
  
  
  CONCLUSIONS
  Serologic response was satisfactory in DPs, whichever dialysis mode (DPD or HDP). It was low in RTRs as compared to DPs.
authors.affiliation: Nephrology IFRNT, University Hospital, Le Kremlin Bicetre, France. severine.beaudreuil@bct.aphp.fr
authors.forename: Séverine
authors.initials: S
authors.lastname: Beaudreuil
authors.forename: Anne
authors.initials: A
authors.lastname: Krivine
authors.forename: Hadia
authors.initials: H
authors.lastname: Hebibi
authors.forename: Béatrice
authors.initials: B
authors.lastname: Ducot
authors.forename: Anne-Aurélie
authors.initials: AA
authors.lastname: Mazet
authors.forename: Yacine
authors.initials: Y
authors.lastname: Taouffik
authors.forename: Alexandre
authors.initials: A
authors.lastname: Seidowsky
authors.forename: Antoine
authors.initials: A
authors.lastname: Jacquet
authors.forename: Hans Kristian
authors.initials: HK
authors.lastname: Lorenzo
authors.forename: Bernard
authors.initials: B
authors.lastname: Charpentier
authors.forename: Hélène
authors.initials: H
authors.lastname: Francois
authors.forename: Antoine
authors.initials: A
authors.lastname: Durrbach
mesh_terms: D000276:Adjuvants, Immunologic; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000914:Antibodies, Viral / Q000097:blood; D005260:Female; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000276:immunology; D007251:Influenza, Human / Q000276:immunology* / Q000517:prevention & control*; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D006435:Renal Dialysis; D014611:Vaccination
chemical_list: D000276:Adjuvants, Immunologic; D000914:Antibodies, Viral; D007252:Influenza Vaccines